BEOVU
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BEOVU (BEOVU).
Brolucizumab is a humanized monoclonal antibody Fab fragment that inhibits vascular endothelial growth factor (VEGF)-A, preventing its binding to VEGFR-1 and VEGFR-2 receptors, thereby reducing endothelial cell proliferation, neovascularization, and vascular permeability.
| Metabolism | As a monoclonal antibody Fab fragment, brolucizumab is metabolized into small peptides and amino acids via general proteolytic pathways; specific CYP enzyme involvement is not expected. |
| Excretion | Primarily metabolic clearance; <1% excreted unchanged in urine. Biliary/fecal excretion not characterized for parent drug. |
| Half-life | Terminal half-life approximately 26 days (range 23-31 days) in patients with neovascular age-related macular degeneration, supporting monthly intravitreal dosing. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin and immunoglobulins. |
| Volume of Distribution | Volume of distribution approximately 0.07-0.09 L/kg, indicating limited extravascular distribution due to large molecular size (150 kDa) and confinement to systemic circulation after intravitreal administration. |
| Bioavailability | Intravitreal: 100% (administered directly into vitreous); not administered systemically; no oral bioavailability. |
| Onset of Action | Intravitreal: Improvement in best-corrected visual acuity observed as early as 1 week after first injection; maximal effect typically by 8-12 weeks. |
| Duration of Action | Duration of effect persists for approximately 8-12 weeks after single intravitreal injection, consistent with monthly to every 2-month dosing intervals in clinical trials. |
0.5 mg (0.05 mL of 10 mg/mL solution) by intravitreal injection once every 4 weeks (monthly) for 12 months, then may be extended to once every 8 weeks (every 2 months) based on clinical response.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required in patients with renal impairment including those on dialysis. GFR-based modifications are not necessary. |
| Liver impairment | No dose adjustment required in patients with hepatic impairment. Child-Pugh-based modifications are not necessary. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no specific weight-based dosing guidelines available. |
| Geriatric use | No specific dose adjustment required in elderly patients; clinical studies included patients aged 65 years and older with similar safety and efficacy as younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BEOVU (BEOVU).
| Breastfeeding | No data on presence in human milk; effects on breastfed infant unknown. Systemic absorption is negligible; however, due to potential for adverse effects, caution advised. Consider developmental and health benefits of breastfeeding along with mother's clinical need. |
| Teratogenic Risk | BEOVU (brolucizumab) is an anti-VEGF agent. Systemic exposure is low, but based on mechanism, there is theoretical risk of impaired angiogenesis in fetus. No adequate human data; animal studies show no evidence of fetal harm at clinically relevant exposures. Risk cannot be excluded; use only if potential benefit justifies potential risk. Avoid in first trimester if possible. |
■ FDA Black Box Warning
Intravitreal injections, including those with Beovu, have been associated with endophthalmitis, retinal detachments, and retinal vasculitis with or without retinal vascular occlusion, which may lead to permanent vision loss.
| Serious Effects |
["Ocular or periocular infections","Active intraocular inflammation"]
| Precautions | ["Intraocular inflammation including retinal vasculitis and retinal vascular occlusion","Increased intraocular pressure","Arterial thromboembolic events following intravitreal injection","Risk of endophthalmitis and retinal detachment with injection procedure"] |
| Food/Dietary | No specific food interactions reported. Follow a heart-healthy diet as recommended for macular degeneration management. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine pregnancy management. Monitor for intraocular inflammation (rare) as per standard of care. In pregnancy, consider fetal ultrasound to detect any anomalies if exposed during first trimester. |
| Fertility Effects | No fertility studies in humans; animal studies show no impairment of fertility at doses up to 1 mg/eye every 3 weeks. Theoretical risk due to anti-VEGF activity on reproductive tissues, but unlikely at ocular doses. |
| Clinical Pearls | BEOVU (brolucizumab) is a VEGF inhibitor for neovascular age-related macular degeneration (nAMD). It has smaller molecular size than other anti-VEGFs, potentially enabling higher molar dose and deeper retinal penetration. Note risk of intraocular inflammation, including retinal vasculitis and retinal vascular occlusion, especially in patients with prior inflammation. Use caution in patients with active ocular infections or uncontrolled glaucoma. Administer via intravitreal injection every 4 weeks for first 3 doses, then every 8-12 weeks based on clinical response. Monitor for vision loss, floaters, or photopsia post-injection. |
| Patient Advice | This medication is injected into your eye by a doctor. · You may need to receive injections every month for the first 3 doses, then every 2-3 months. · Avoid rubbing or pressing on the treated eye after injection. · Contact your doctor immediately if you experience eye pain, redness, worsening vision, or sensitivity to light. · Do not drive or operate machinery immediately after injection until vision clears. · Inform your doctor about all other medications, especially blood thinners. · Regular eye exams are necessary to monitor treatment response. · Seek emergency care if you have severe headache, stroke-like symptoms, or sudden vision loss. |